Finotonlimab (PD-1 inhibitor) plus bevacizumab (bevacizumab biosimilar) as first-tier therapy for late-stage hepatocellular carcinoma: a randomized phase 2/3 trialChuanhua Zhao, Chuan Jin, Zhuang Li et al.|Signal Transduction and Targeted Therapy|2025Cited by 20
Continuous Low-Dose Apatinib Combined With WBRT Significantly Reduces Peritumoral Edema and Enhances the Efficacy of Symptomatic Multiple Brain Metastases in NSCLCYue Ren, Yuming Jia, Shan‐Bing Wang et al.|Technology in Cancer Research & Treatment|2021Cited by 8
P3.01-48 The Efficiency of Low-Dose Apatinib in Treatment of Advanced Lung Squamous Cell CarcinomaYuming Jia, Yansheng Jiang, Tao Li et al.|Journal of Thoracic Oncology|2018Cited by 1